메뉴 건너뛰기




Volumn 27, Issue 8, 2013, Pages 1715-1721

Lenalidomide in combination with an activin A-neutralizing antibody: Preclinical rationale for a novel anti-myeloma strategy

Author keywords

activin A; lenalidomide; myeloma

Indexed keywords

ACTIVIN A; LENALIDOMIDE; NEUTRALIZING ANTIBODY; PROTEIN C JUN; PROTEIN KINASE B;

EID: 84881475207     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.50     Document Type: Article
Times cited : (43)

References (39)
  • 1
    • 79952721484 scopus 로고    scopus 로고
    • Advances in the biology and treatment of bone disease in multiple myeloma
    • Raje N, Roodman GD. Advances in the biology and treatment of bone disease in multiple myeloma. Clin Cancer Res 2011; 17: 1278-1286.
    • (2011) Clin Cancer Res , vol.17 , pp. 1278-1286
    • Raje, N.1    Roodman, G.D.2
  • 2
    • 0024786736 scopus 로고
    • Mechanisms of bone destruction in multiple myeloma: The importance of an unbalanced process in determining the severity of lytic bone disease
    • Bataille R, Chappard D, Marcelli C, Dessauw P, Sany J, Baldet P et al. Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. J Clin Oncol 1989; 7: 1909-1914. (Pubitemid 20014340)
    • (1989) Journal of Clinical Oncology , vol.7 , Issue.12 , pp. 1909-1914
    • Bataille, R.1    Chappard, D.2    Marcelli, C.3    Dessauw, P.4    Sany, J.5    Baldet, P.6    Alexandre, C.7
  • 3
    • 33751193178 scopus 로고    scopus 로고
    • Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition
    • DOI 10.1182/blood-2006-05-026112
    • Giuliani N, Rizzoli V, Roodman GD. Multiple myeloma bone disease: pathophy-siology of osteoblast inhibition. Blood 2006; 108: 3992-3996. (Pubitemid 44913267)
    • (2006) Blood , vol.108 , Issue.13 , pp. 3992-3996
    • Giuliani, N.1    Rizzoli, V.2    Roodman, G.D.3
  • 4
    • 47649085380 scopus 로고    scopus 로고
    • Thalidomide and lenalidomide: Mechanism-based potential drug combinations
    • DOI 10.1080/10428190802005191, PII 792758569
    • Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson KC. Thalidomide and lenalidomide: mechanism-based potential drug combinations. Leuk Lymphoma 2008; 49: 1238-1245. (Pubitemid 352015786)
    • (2008) Leukemia and Lymphoma , vol.49 , Issue.7 , pp. 1238-1245
    • Vallet, S.1    Palumbo, A.2    Raje, N.3    Boccadoro, M.4    Anderson, K.C.5
  • 6
    • 54049156803 scopus 로고    scopus 로고
    • Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma
    • Breitkreutz I, Raab MS, Vallet S, Hideshima T, Raje N, Mitsiades C et al. Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia 2008; 22: 1925-1932.
    • (2008) Leukemia , vol.22 , pp. 1925-1932
    • Breitkreutz, I.1    Raab, M.S.2    Vallet, S.3    Hideshima, T.4    Raje, N.5    Mitsiades, C.6
  • 7
    • 77950438331 scopus 로고    scopus 로고
    • Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease
    • Vallet S, Mukherjee S, Vaghela N, Hideshima T, Fulciniti M, Pozzi S et al. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci USA 2010; 107: 5124-5129.
    • (2010) Proc Natl Acad Sci USA , vol.107 , pp. 5124-5129
    • Vallet, S.1    Mukherjee, S.2    Vaghela, N.3    Hideshima, T.4    Fulciniti, M.5    Pozzi, S.6
  • 9
    • 77951579858 scopus 로고    scopus 로고
    • AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition
    • Santo L, Vallet S, Hideshima T, Cirstea D, Ikeda H, Pozzi S et al. AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3beta activation and RNA polymerase II inhibition. Oncogene 2010; 29: 2325-2336.
    • (2010) Oncogene , vol.29 , pp. 2325-2336
    • Santo, L.1    Vallet, S.2    Hideshima, T.3    Cirstea, D.4    Ikeda, H.5    Pozzi, S.6
  • 10
    • 70349439276 scopus 로고    scopus 로고
    • High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties
    • Pozzi S, Vallet S, Mukherjee S, Cirstea D, Vaghela N, Santo L et al. High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin Cancer Res 2009; 15: 5829-5839.
    • (2009) Clin Cancer Res , vol.15 , pp. 5829-5839
    • Pozzi, S.1    Vallet, S.2    Mukherjee, S.3    Cirstea, D.4    Vaghela, N.5    Santo, L.6
  • 13
    • 67349099081 scopus 로고    scopus 로고
    • Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma
    • Raje N, Hideshima T, Mukherjee S, Raab M, Vallet S, Chhetri S et al. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma. Leukemia 2009; 23: 961-970.
    • (2009) Leukemia , vol.23 , pp. 961-970
    • Raje, N.1    Hideshima, T.2    Mukherjee, S.3    Raab, M.4    Vallet, S.5    Chhetri, S.6
  • 14
    • 51349137097 scopus 로고    scopus 로고
    • Dlx5, a positive regulator of osteoblastogenesis, is essential for osteoblast-osteoclast coupling
    • Samee N, Geoffroy V, Marty C, Schiltz C, Vieux-Rochas M, Levi G et al. Dlx5, a positive regulator of osteoblastogenesis, is essential for osteoblast-osteoclast coupling. Am J Pathol 2008; 173: 773-780.
    • (2008) Am J Pathol , vol.173 , pp. 773-780
    • Samee, N.1    Geoffroy, V.2    Marty, C.3    Schiltz, C.4    Vieux-Rochas, M.5    Levi, G.6
  • 15
    • 74949100969 scopus 로고    scopus 로고
    • Pathogenesis of myeloma bone disease
    • Roodman GD. Pathogenesis of myeloma bone disease. J Cell Biochem 2010; 109: 283-291.
    • (2010) J Cell Biochem , vol.109 , pp. 283-291
    • Roodman, G.D.1
  • 16
    • 23744498205 scopus 로고    scopus 로고
    • Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation
    • DOI 10.1182/blood-2004-12-4986
    • Giuliani N, Colla S, Morandi F, Lazzaretti M, Sala R, Bonomini S et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 2005; 106: 2472-2483. (Pubitemid 41510822)
    • (2005) Blood , vol.106 , Issue.7 , pp. 2472-2483
    • Giuliani, N.1    Colla, S.2    Morandi, F.3    Lazzaretti, M.4    Sala, R.5    Bonomini, S.6    Grano, M.7    Colucci, S.8    Svaldi, M.9    Rizzoli, V.10
  • 21
    • 0035958517 scopus 로고    scopus 로고
    • The role of tumor necrosis factor α in the pathophysiology of human multiple myeloma: Therapeutic applications
    • DOI 10.1038/sj.onc.1204623
    • Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001; 20: 4519-4527. (Pubitemid 32772434)
    • (2001) Oncogene , vol.20 , Issue.33 , pp. 4519-4527
    • Hideshima, T.1    Chauhan, D.2    Schlossman, R.3    Richardson, P.4    Anderson, K.C.5
  • 22
    • 51049087523 scopus 로고    scopus 로고
    • Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation
    • Munemasa S, Sakai A, Kuroda Y, Okikawa Y, Katayama Y, Asaoku H et al. Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation. Int J Oncol 2008; 33: 129-136.
    • (2008) Int J Oncol , vol.33 , pp. 129-136
    • Munemasa, S.1    Sakai, A.2    Kuroda, Y.3    Okikawa, Y.4    Katayama, Y.5    Asaoku, H.6
  • 23
    • 74849092530 scopus 로고    scopus 로고
    • Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: In vitro effect of Bortezomib and Lenalidomide
    • De Matteo M, Brunetti AE, Maiorano E, Cafforio P, Dammacco F, Silvestris F. Constitutive down-regulation of Osterix in osteoblasts from myeloma patients: in vitro effect of Bortezomib and Lenalidomide. Leuk Res 2010; 34: 243-249.
    • (2010) Leuk Res , vol.34 , pp. 243-249
    • De Matteo, M.1    Brunetti, A.E.2    Maiorano, E.3    Cafforio, P.4    Dammacco, F.5    Silvestris, F.6
  • 24
    • 34548128339 scopus 로고    scopus 로고
    • The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma
    • DOI 10.1038/sj.leu.2404843, PII 2404843
    • Terpos E, Dimopoulos MA, Sezer O. The effect of novel anti-myeloma agents on bone metabolism of patients with multiple myeloma. Leukemia 2007; 21: 1875-1884. (Pubitemid 47299959)
    • (2007) Leukemia , vol.21 , Issue.9 , pp. 1875-1884
    • Terpos, E.1    Dimopoulos, M.-A.2    Sezer, O.3
  • 25
    • 0033231930 scopus 로고    scopus 로고
    • Inhibitory effects of activin-A on osteoblast differentiation during cultures of fetal rat calvarial cells
    • DOI 10.1002/(SICI)1097-4644(19991101)75:2<206::AID-JCB3>3.0.CO;2-T
    • Ikenoue T, Jingushi S, Urabe K, Okazaki K, Iwamoto Y. Inhibitory effects of activin-A on osteoblast differentiation during cultures of fetal rat calvarial cells. J Cell Biochem 1999; 75: 206-214. (Pubitemid 29463489)
    • (1999) Journal of Cellular Biochemistry , vol.75 , Issue.2 , pp. 206-214
    • Ikenoue, T.1    Jingushi, S.2    Urabe, K.3    Okazaki, K.4    Iwamoto, Y.5
  • 28
    • 0037403844 scopus 로고    scopus 로고
    • BMP signals regulate Dlx5 during early avian skull development
    • DOI 10.1016/S0012-1606(03)00059-9
    • Holleville N, Quilhac A, Bontoux M, Monsoro-Burq AH. BMP signals regulate Dlx5 during early avian skull development. Dev Biol 2003; 257: 177-189. (Pubitemid 36438652)
    • (2003) Developmental Biology , vol.257 , Issue.1 , pp. 177-189
    • Holleville, N.1    Quilhac, A.2    Bontoux, M.3    Monsoro-Burq, A.-H.4
  • 29
    • 0042891942 scopus 로고    scopus 로고
    • BMP-2-induced Runx2 expression is mediated by Dlx5, and TGF-beta 1 opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 expression
    • Lee MH, Kim YJ, Kim HJ, Park HD, Kang AR, Kyung HM et al. BMP-2-induced Runx2 expression is mediated by Dlx5, and TGF-beta 1 opposes the BMP-2-induced osteoblast differentiation by suppression of Dlx5 expression. J Biol Chem 2003; 278: 34387-34394.
    • (2003) J Biol Chem , vol.278 , pp. 34387-34394
    • Lee, M.H.1    Kim, Y.J.2    Kim, H.J.3    Park, H.D.4    Kang, A.R.5    Kyung, H.M.6
  • 30
    • 80051473281 scopus 로고    scopus 로고
    • Crosstalk between Nodal/activin and MAPK p38 signaling is essential for anterior-posterior axis specification
    • Clements M, Pernaute B, Vella F, Rodriguez TA. Crosstalk between Nodal/activin and MAPK p38 signaling is essential for anterior-posterior axis specification. Curr Biol 2011; 21: 1289-1295.
    • (2011) Curr Biol , vol.21 , pp. 1289-1295
    • Clements, M.1    Pernaute, B.2    Vella, F.3    Rodriguez, T.A.4
  • 31
    • 77957734208 scopus 로고    scopus 로고
    • Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss
    • Raje N, Vallet S. Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss. Curr Opin Mol Ther 2010; 12: 586-597.
    • (2010) Curr Opin Mol Ther , vol.12 , pp. 586-597
    • Raje, N.1    Vallet, S.2
  • 32
    • 77956497430 scopus 로고    scopus 로고
    • RAP-011, a soluble activin receptor type IIA IgG-Fc-fusion protein, is a novel bone anabolic agent that prevents bone loss in a mouse model of metastatic breast cancer
    • Mulivor AW, Barbosa D, Kumar R, Pearsall AE, Underwood KW, Ucran JA et al. RAP-011, a soluble activin receptor type IIA IgG-Fc-fusion protein, is a novel bone anabolic agent that prevents bone loss in a mouse model of metastatic breast cancer. Bone 2008; 44(Supplement 2): S221-S222.
    • (2008) Bone , vol.44 , Issue.SUPPL. 2
    • Mulivor, A.W.1    Barbosa, D.2    Kumar, R.3    Pearsall, A.E.4    Underwood, K.W.5    Ucran, J.A.6
  • 34
    • 0026595714 scopus 로고
    • Effect of activin A on globin gene expression in purified human erythroid progenitors
    • Shao L, Frigon Jr. NL, Young AL, Yu AL, Mathews LS, Vaughan J et al. Effect of activin A on globin gene expression in purified human erythroid progenitors. Blood 1992; 79: 773-781.
    • (1992) Blood , vol.79 , pp. 773-781
    • Shao, L.1    Frigon, Jr.N.L.2    Young, A.L.3    Yu, A.L.4    Mathews, L.S.5    Vaughan, J.6
  • 35
    • 0026565263 scopus 로고
    • Evidence for the participation of endogenous activin A/erythroid differentiation factor in the regulation of erythropoiesis
    • Shiozaki M, Sakai R, Tabuchi M, Nakamura T, Sugino K, Sugino H et al. Evidence for the participation of endogenous activin A/erythroid differentiation factor in the regulation of erythropoiesis. Proc Natl Acad Sci USA 1992; 89: 1553-1556.
    • (1992) Proc Natl Acad Sci USA , vol.89 , pp. 1553-1556
    • Shiozaki, M.1    Sakai, R.2    Tabuchi, M.3    Nakamura, T.4    Sugino, K.5    Sugino, H.6
  • 36
    • 65549147617 scopus 로고    scopus 로고
    • Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women
    • Ruckle J, Jacobs M, Kramer W, Pearsall AE, Kumar R, Underwood KW et al. Single-dose, randomized, double-blind, placebo-controlled study of ACE-011 (ActRIIA-IgG1) in postmenopausal women. J Bone Miner Res 2009; 24: 744-752.
    • (2009) J Bone Miner Res , vol.24 , pp. 744-752
    • Ruckle, J.1    Jacobs, M.2    Kramer, W.3    Pearsall, A.E.4    Kumar, R.5    Underwood, K.W.6
  • 37
    • 33750607347 scopus 로고    scopus 로고
    • A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma
    • Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108: 3458-3464.
    • (2006) Blood , vol.108 , pp. 3458-3464
    • Richardson, P.G.1    Blood, E.2    Mitsiades, C.S.3    Jagannath, S.4    Zeldenrust, S.R.5    Alsina, M.6
  • 38
    • 68249135722 scopus 로고    scopus 로고
    • Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
    • Richardson P, Jagannath S, Hussein M, Berenson J, Singhal S, Irwin D et al. Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma. Blood 2009; 114: 772-778.
    • (2009) Blood , vol.114 , pp. 772-778
    • Richardson, P.1    Jagannath, S.2    Hussein, M.3    Berenson, J.4    Singhal, S.5    Irwin, D.6
  • 39
    • 77956555237 scopus 로고    scopus 로고
    • ACE-011, a soluble activin receptor type Iia IgG-Fc fusion protein, increases hemoglobin (Hb) and improves bone lesions in multiple myeloma patients receiving myelosuppressive chemotherapy: Preliminary analysis
    • abstract
    • Abdulkadyrov KM, Salogub GN, Khuazheva NK, Woolf R, Haltom E, Borgstein NG et al. ACE-011, a soluble activin receptor type Iia IgG-Fc fusion protein, increases hemoglobin (Hb) and improves bone lesions in multiple myeloma patients receiving myelosuppressive chemotherapy: preliminary analysis,. Blood 2009; 114: 749 abstract.
    • (2009) Blood , vol.114 , pp. 749
    • Abdulkadyrov, K.M.1    Salogub, G.N.2    Khuazheva, N.K.3    Woolf, R.4    Haltom, E.5    Borgstein, N.G.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.